Alan Prem KUMAR

Dr Alan Prem Kumar’s group focuses on the study of metastatic disease, specifically in breast cancer. Over 90 percent of the morbidity and mortality that results from cancer is due to metastasis. Thus, the understanding of this process is crucial to the development of novel therapies for cancer patients. Discoveries in these areas lead to the identification of a novel oncogene that regulates key pathways controlling cell proliferation, migration and drug resistance in breast, prostate, gastric, and colon cancers. His second research area is to understand the roles of nuclear receptors and epigenetics in regulating gene expression in breast cancer so that we can develop more effective and safer drug treatment for patients. Development of molecular therapeutics and biomarkers of drug action in breast cancer is also of great interest within his group.

Metastatic cancers are generally considered to be incurable; therefore, new prognostic markers are urgently needed to identify patients at the highest risk for developing metastases and to enable oncologists to begin tailoring targeted treatments. We recently identified a novel oncogene whose function in various cancers is attributable to its ability to activate oncogenic pathways whose hyperactivity is functionally linked to cancer progression and to acquisition of resistance to chemotherapy. Current research focuses on better understanding the role of this oncogene that offers great potential for the development of more specifically targeted treatment in the battle against cancer and metastatic disease.

Dr Kumar’s second research interest is to understand how nuclear receptors regulate gene expression to affect alterations in phenotype and physiology in response to hormones. Nuclear receptors constitute a discrete gene family encoding ligand-activated transcription factors, which includes orphan receptors whose ligands and functions are unknown. Orphan receptors, which constitute half of the 48-gene family, are part of the druggable genome and represent a current and future growth area in biomedical research. Understanding the novel physiological roles and mechanisms of action of these receptors with special interest in post-translational modification including phosphorylation, acetylation, and SUMOylation will ultimately translate into understanding human disease and ultimately developing novel treatments and therapies.

Over the years, Dr Kumar has forged relationships with scientists and oncologists in cancer research and established industry alignment projects with Davos Life Science, Singapore; GenoMed Inc, USA; Daiichi Sankyo Inc, USA and Pascual Pharma Inc, Philippines.

Selected Publications:

  1. Goh JN, Loo SY, Datta A, Siveen KS, Yap WN, Cai W, Shin EM, Wang C, Kim JE, Chan M, Dharmarajan AM, Lee AS, Lobie PE, Yap CT*, Kumar AP*. microRNAs in breast cancer: regulatory roles governing the hallmarks of cancer. Biol Rev Camb Philos Soc. 2015 Jan 28. doi: 10.1111/brv.12176. [Epub ahead of print]. *co-senior authors (IF=9.79).
  2. Shin EM, Hay HS, Lee MH, Goh JN, Tan TZ, Sen YP, Lim SW, Yousef EM, Ong HT, Thike AA, Kong X, Wu Z, Mendoz E, Sun W, Salto-Tellez M, Lim CT, Lobie PE, Lim YP, Yap CT, Zeng Q, Sethi G, Lee MB, Tan P, Goh BC, Miller LD, Thiery JP, Zhu T, Gaboury L, Tan PH, Hui KM, Yip GW, Miyamoto S, Kumar AP*, Tergaonkar V*. DEAD-box Helicase DP103 Defines the Metastatic Potential of Human Breast Cancers. J Clin Invest. 2014 Sep 2;124(9):3807-24. *co-senior authors (IF= 13.765).
  3. Kumar AP, Loo SY, Shin SW, Tuan ZT, Eng CB, Singh R, Putti TC, Ong CW, Salto-Tellez M, Goh BC, Park JI, Thiery JP, Pervaiz S, Clement MV. Targeting MnSOD in Basal Breast Carcinoma using Agonists of PPARγ: a new strategy for enhancing chemosensitivity. Antioxid Redox Signal. 2014 May 20;20(15):2326-46. (IF= 7.667)
  4. Surana R, Sikka S, Cai W, Shin EM, Warrier SR, Tan HJG, Arfuso F, Fox SA, Dharmarajan AM*, Kumar AP*. Secreted Frizzled Related Proteins: Implications in Cancers. BBA Reviews on Cancer 2014 Jan;1845(1):53-65.*co-senior authors. (IF=7.584).
  5. Zhu Y, Casey PJ, Kumar AP, Pervaiz S. Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases. Cell Death Dis. 2013 Apr 4;4:e568. (IF= 5.177).
  6. Ramachandran L, Manu KA, Shanmugam MK, Li F, Siveen KS, Vali S, Kapoor S, Abbasi T, Surana R, Smoot DT, Ashktorab H, Tan P, Ahn KS, Yap CW, Kumar AP*, Sethi G*.Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor γ activation pathway in gastric cancer. J Biol Chem. 2012 Nov 2;287(45):38028-40. *co-senior authors. (IF=4.6).
  7. Kanjoormana M, Shanmugam MK, Ramachandran L, Li F, Fong CW, Kumar AP, Tan P, Sethi G. First evidence that g-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-kB pathway. Clin Cancer Res. 2012 Apr 15;18(8):2220-9. (IF=8.193).
  8. Rajendran P, Ong TH, Chen L, Li F, Shanmugam MK, Valli S, Abbasi T, Kapoor S, Sharma A, Kumar AP, Hui KM, Sethi G. Suppression of Signal Transducer and Activator of Transcription 3 Activation by Butein Inhibits Growth of Human Hepatocellular Carcinoma in vivo. Clin Cancer Res. 2011 Mar 15;17(6):1425-39. (IF=8.193).
  9. Kumar AP, Quake AL, Chang MK, Zhou T, Lim KS, Singh R, Hewitt RE, Salto-Tellez M, Pervaiz S, Clément MV. Repression of NHE1 Expression by PPAR{gamma} Activation Is a Potential New Approach for Specific Inhibition of the Growth of Tumor Cells In vitro and In vivo. Cancer Res. 2009 Nov 15;69(22):8636-44. (IF=9.284).
  10. Kumar, AP*; Chang, MKX*; Fliegel, L; Pervaiz, S; Clement, MV. Oxidative repression of NHE1 gene expression involves iron-mediated caspase activity. Cell Death Differ.2007 Oct;14(10):1733-46.4 *co-lead authors. (IF=8.371).
Name Alan Prem KUMAR
Affiliations Principal Associate, Cancer Science Institute of Singapore, National University of Singapore
Assistant Professor, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore
Adjunct Associate Professor, Department of Biological Sciences, University of North Texas, USA
Adjunct Principal Research Fellow (Associate Professor), School of Biomedical Sciences, Faculty of Health Sciences, Curtin University, Australia
Email csiapk[at]nus.edu.sg ;  phcapk[at]nus.edu.sg

Education

Institute Degree (if applicable) Year(s)
University of North Texas, USA Ph.D 2000
University of North Texas, USA MSc 1995
University of North Texas, USA BSc 1992

Professional Experience

Adjunct Associate Professor, Department of Biological
Sciences, University of North Texas, USA
2014 – present
Adjunct Principal Research Fellow (Associate Professor),
School of Biomedical Sciences, Faculty of Health Sciences,
Curtin University, Australia
2014 – present
Principle Associate, Cancer Science Institute
of Singapore, NUS
2013 – present
Scientific Advisory Board, Pascual Pharma Inc, Philippines 2013 – present
Assistant Professor, Cancer Science Institute of Singapore 2012 – Present
Assistant Professor, Department of Pharmacology, YLL
School of Medicine, NUS
2012 – Present
Chairman, Pre-graduate Students Academic Committee, CSI
Singapore
2011 – Present
Executive Committee (Education Sub-Committee), SINDA,
Singapore
2009 – Present
Scientific Advisory Board, GenoMed, Inc., Aventura, FL,
USA
2009 – Present
Visiting Scientist, Curtin University, Western Australia 2012 – 2014
John Nott Cancer Fellow, Cancer Council Western Australia 2012 – 2013
Scientific Advisory Board, Bioexplore, India 2011 – 2013
Scientific Advisory Board, BioSciences Research Institute,
Chennai, India
2009 – 2013
Visiting Scientist, University of Western Australia,
Western Australia
2011 – 2012
School Advisory Committee, Gan Eng Seng School, Singapore 2010 – 2012
Senior Research Scientist, Department of Pharmacology, YLL
School of Medicine, NUS
2010 – 2012
Senior Research Scientist, Cancer Science Institute of
Singapore, NUS
2010 – 2012
Senior Research Scientist, National University Medical
Institutes, NUS
2009 – 2010
Research Scientist, National University Medical
Institutes, NUS
2004 – 2009
Post-Doctoral Fellow, Sidney Kimmel Cancer Center, San
Diego, California, USA
2001 – 2004
Teaching Coordinator, University of North Texas, USA 1993 – 2000

YUAN Yi

Research Fellow

Development of Novel Src Inhibitors for Treatment of Triple Negative Breast Cancer

KANCHI Madhu Mathi

Research Assistant

Characterization of a Novel Regulator of Metabolic Re-programming in Triple Negative Breast Cancer

WANG Chao

Research Assistant

Characterization of a Novel Regulator of Mevalonate Metabolism in Triple Negative Breast Cancer

YAP Wei Ney

NUS-Industry PhD student

Pre-clinical and Clinical Assessment of an Industry Proprietary Topical Cream for Prevention of UVB-induced Skin Photocarcinogenesis

Shikha Satendra SINGH

PhD student

Characterization of a Novel Regulator of PI3K/mTOR Pathway in Invasive Gastric Cancer.

CAI Wanpei

PhD student

Characterization of a Novel Regulator of Wnt signaling in Basal Breast Carcinoma

Shreya KAR

President’s Scholar PhD student

Novel Microenvironmental Regulators of Tumor Progression and Metastasis in Triple Negative Breast Cancer

Publication Impact Factor Award for Adjunct Publishing, Curtin University, Western Australia 2014
Publication Impact Factor Award for Adjunct Publishing, Curtin University, Western Australia 2012
John Nott Cancer Fellowship, Cancer Council Western Australia 2012 – 13
AACR-ITO EN, Ltd. Award, American Association for Cancer Research Annual Meeting 2008
Award from Society of Free Radical Biology and Medicine, Washington DC, USA 2007
Postdoctoral Fellowship, Sidney Kimmel Cancer Center 2001 – 04
Outstanding Teaching Award, Department of Biological Sciences, University of North Texas, USA 1999
Texas Public Education Grant, University of North Texas, USA 1995